Abstract:Background: The current compendial assay for haemagglutinin antigen potency in influenza vaccine is the single radial immunodiffusion (SRID) which is time consuming and can lead to delays in release of vaccine. We previously described an alternate capture and detection enzyme linked immunoassay (ELISA) that utilizes sub-type specific, sub-clade cross-reactive monoclonal antibodies (mAbs) that are haemagglutination inhibiting (HAI) and correlate with SRID. The aim of this study is to determine the applicability of ELISA across current platforms for quantitation of seasonal quadrivalent vaccine. Methods: A single mAb capture and detection ELISA was employed to quantitate hemagglutinin (HA) derived from different vaccine platforms and host organisms and compared to SRID and a polyclonal antibody based ELISA. Results: We selected mAbs that displayed appropriate characteristics for a stability indicating potency assay which reacted to avian, insect and mammalian derived HA. Qualification of the homologous mAb assay against egg and cell derived HA demonstrated performance similar to that of the SRID however, superiority in sensitivity and specificity against strains from both influenza B/Victoria and B/Yamagata lineages. Analysis of drifted strains across multiple seasons demonstrated continued utility of this approach, reducing the need to develop reagents each season. With modification of the assay, we were able to accurately measure HA from different platforms and process stages using a single calibrated reference standard. We demonstrated the accuracy of ELISA when testing vaccine formulations containing selected adjuvants at standard and higher concentrations. Accelerated stability analysis indicated a strong correlation in the rate of degradation between the homologous mAb ELISA and SRID but not with ELISA utilizing polyclonal antisera. Further, we demonstrated specificity was restricted to the trimeric and oligomeric forms of HA but not monomeric HA. Conclusion: We believe this homologous mAb ELISA is a suitable replacement for the SRID compendial assay for HA antigen quantitation and stability assessment. Identification of suitable mAbs that are applicable across multiple vaccine platforms with extended sub-type reactivity across a number of influenza seasons, indicate that this assay has broad applicability, leading to earlier availability of seasonal and pandemic vaccines without frequent replacement of polyclonal antisera that is required with SRID.

Development and Validation of Alternative Method for Determination of Haemagglutinin Content in Influenza Vaccine

Application of Alternative Method for Haemagglutinin Determination in Pandemic A(H1N1) Influenza Vaccine Development

Application of Deglycosylation and Electrophoresis to the Quantification of Influenza Viral Hemagglutinins Facilitating the Production of 2009 Pandemic Influenza (H1N1) Vaccines at Multiple Manufacturing Sites in China

Collaborative Studies on the Development of National Reference Standards for Potency Determination of H7N9 Influenza Vaccine.

Selective and quantitative detection of influenza virus proteins in commercial vaccines using two-dimensional high-performance liquid chromatography and fluorescence detection

Identification and Analysis of B Cell Epitopes of Hemagglutinin of H1N1 Influenza Virus.

An ELISA-based assay for determining haemagglutinin potency in egg, cell, or recombinant protein derived influenza vaccines

Quantitative Determination of Free Polysaccharide Content in Haemophilus influenzae Type b Conjugate Vaccine by Acid Precipitation with Sodium Deoxycholate

[Preparation and Identification of High Immunogenic A/PR/8/34 Maternal Strain HA Protein for Influenza Virus Classical Reassortment].

A Rapid Virus‐Free Method for Producing Influenza HA Immunogen Needed for Preparation of Influenza Vaccine Potency Antisera Reagents

Removal of Interference in Lowry Method for Determination of Protein Content in Haemophilus Influenza Type B Conjngate Vaccine

Development of One-Step Real-Time PCR Assay for Titrating Trivalent Live Attenuated Influenza Vaccines

Establishment of a TaqMan-based Real-Time Quantitative PCR Method for Detection of Exogenous Fowl Adenovirus Type Ⅰ, Type Ⅲ and Avian Leukosis Virus in Human Cold Adapted Live Attenuated Influenza Vaccines

Analysing the Potency of a Seasonal Influenza Vaccine Using Reference Antisera from Heterologous Strains

A Single-Step Method for Harvesting Influenza Viral Particles from MDCK Cell Culture Supernatant with High Yield and Effective Impurity Removal

Rapid Estimation of Binding Activity of Influenza Virus Hemagglutinin to Human and Avian Receptors

Formulation development of a plant-derived H1N1 influenza vaccine containing purified recombinant hemagglutinin antigen

Identification of Linear Peptide Immunogens with Verified Broad-spectrum Immunogenicity from the Conserved Regions within the Hemagglutinin Stem Domain of H1N1 Influenza Virus

Determination of Avian Influenza A (H9N2) Virions by Inductively Coupled Plasma Mass Spectrometry Based Magnetic Immunoassay with Gold Nanoparticles Labeling

Characterization and Immunogenicity of Influenza H7N9 Vaccine Antigens Produced Using a Serum-Free Suspension MDCK Cell-Based Platform

Establishment of National Ovalbumin Quantitation Reference for Quality Control of Influenza Vaccine